Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
CA Lamb, NA Kennedy, T Raine, PA Hendy, PJ Smith… - Gut, 2019 - gut.bmj.com
Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …
Both represent chronic inflammation of the gastrointestinal tract, which displays …
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
S Ramiro, E Nikiphorou, A Sepriano… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
Targeting immune cell circuits and trafficking in inflammatory bowel disease
MF Neurath - Nature immunology, 2019 - nature.com
Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …
characterized by uncontrolled activation of intestinal immune cells in a genetically …
Revisiting fibrosis in inflammatory bowel disease: the gut thickens
Intestinal fibrosis, which is usually the consequence of chronic inflammation, is a common
complication of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative …
complication of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative …
ACG clinical guideline: management of Crohn's disease in adults
GR Lichtenstein, EV Loftus, KL Isaacs… - Official journal of the …, 2018 - journals.lww.com
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic,
immunologic, and environmental influences. The incidence of Crohn's disease has steadily …
immunologic, and environmental influences. The incidence of Crohn's disease has steadily …
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …
selected a panel of 48 experts supported by a team of methodologists and librarians …
[PDF][PDF] Cytokine networks in the pathophysiology of inflammatory bowel disease
M Friedrich, M Pohin, F Powrie - Immunity, 2019 - cell.com
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract. Cytokine-targeted therapies have transformed the treatment of IBD, providing control of …
tract. Cytokine-targeted therapies have transformed the treatment of IBD, providing control of …
COVID-19 and immunomodulation in IBD
MF Neurath - Gut, 2020 - gut.bmj.com
The current coronavirus pandemic is an ongoing global health crisis due to COVID-19,
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
D Van Der Heijde, S Ramiro, R Landewé… - Annals of the …, 2017 - ard.bmj.com
To update and integrate the recommendations for ankylosing spondylitis and the
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …